Incyte Corporation $INCY Shares Newly Acquired by Ground Swell Capital LLC

Ground Swell Capital LLC purchased a new stake in Incyte Corporation (NASDAQ:INCY – Free Report) during the third quarter, HoldingsChannel reports. The institutional investor purchased 4,645 shares of the biopharmaceutical company’s stock, valued at approximately $564,000. Incyte accounts for approximately 1.3% of Ground Swell Capital LLC’s holdings, making the stock its 13th biggest position.

Several other institutional investors and hedge funds also recently modified their holdings of the company. Bellwether Advisors LLC acquired a new stake in Incyte in the 3rd quarter valued at approximately $1,201,000. Phoenix Financial Ltd. acquired a new position in Incyte during the 3rd quarter worth approximately $247,000. Danske Bank A S boosted its position in Incyte by 84.4% during the 3rd quarter. Danske Bank A S now owns 150,974 shares of the biopharmaceutical company’s stock worth $18,321,000 after acquiring an additional 69,112 shares during the last quarter. Allworth Financial LP boosted its position in Incyte by 4.2% during the 3rd quarter. Allworth Financial LP now owns 5,402 shares of the biopharmaceutical company’s stock worth $612,000 after acquiring an additional 220 shares during the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Incyte by 6.1% during the 3rd quarter. Fisher Asset Management LLC now owns 145,442 shares of the biopharmaceutical company’s stock worth $17,649,000 after acquiring an additional 8,424 shares in the last quarter. 96.97% of the stock is owned by institutional investors and hedge funds.

Incyte Stock Performance

INCY traded down $0.73 on Friday, hitting $120.97. 950,394 shares of the company were exchanged, compared to its average volume of 1,785,896. Incyte Corporation has a 12 month low of $89.25 and a 12 month high of $132.60. The company has a market cap of $24.66 billion, a PE ratio of 64.35, a PEG ratio of 4.43 and a beta of 0.78. The stock’s fifty day moving average is $119.18 and its 200-day moving average is $108.96.

Incyte (NASDAQ:INCY – Get Free Report) last issued its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, beating the consensus estimate of ($3.93) by $0.33. The firm had revenue of $1.56 billion during the quarter, compared to analysts’ expectations of $1.46 billion. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The business’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.26 earnings per share. As a group, equities research analysts expect that Incyte Corporation will post 2.24 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CMO Steven Stein sold 240,193 shares of the company’s stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $118.39, for a total transaction of $28,436,449.27. Following the sale, the chief marketing officer owned 30,916 shares in the company, valued at $3,660,145.24. This represents a 88.60% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Thomas Tray sold 610 shares of the stock in a transaction that occurred on Tuesday, November 3rd. The shares were sold at an average price of $118.96, for a total value of $72,565.60. Following the completion of the sale, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. The trade was a 2.81% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 254,246 shares of company stock valued at $30,162,968 in the last 90 days. 16.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of research firms have recently issued reports on INCY. Citigroup reiterated a “buy” rating on shares of Incyte in a report on Monday, August 3rd. Leerink Partners cut their price objective on shares of Incyte from $154.00 to $150.00 and set an “outperform” rating on the stock in a research report on Thursday, November 5th. Barclays increased their target price on shares of Incyte from $139.00 to $143.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Weiss Ratings downgraded shares of Incyte from a “buy (b)” rating to a “hold (c)” rating in a research report on Wednesday, November 4th. Finally, Truist Financial lifted their price target on shares of Incyte from $105.00 to $115.00 and gave the company a “hold” rating in a research note on Wednesday, October 14th. Eleven analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $132.86.

Read Our Latest Report on Incyte

About Incyte

(Free Report)

Incyte is a biopharmaceutical company that discovers, develops and commercializes medicines, with a focus on oncology, hematology and inflammatory and autoimmune diseases. Founded in 1991, the company is headquartered in Wilmington, Delaware, and conducts research and commercial activities in the United States and internationally. Its products include Jakafi (ruxolitinib), used to treat certain blood disorders and graft-versus-host disease, and Opzelura (ruxolitinib cream), approved in the United States for certain skin conditions.

Further Reading

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY – Free Report).

Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.